DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc > Stock price could hit $5.00US by end of week.

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Apr 10, 2019 10:25pm

56 Views

Post# 29610611

RE:RE:RE:Stock price could hit $5.00US by end of week.

Pugsrock2 wrote: Not even 5$ CAD. PATHETIC. Sitting here on the market makers yoyo. Some news someday might be helpful

I was surprised at the timing of their move to the Nasdaq. I thought it might be timed around an event that would bring some recognition to the progress they are making but not the case.

Here we are 3 months later and although they have a couple of news releases there is nothing that is attracting good attention to their potential. So it seems their financing was off and their timing was off.

<< Previous

Bullboard Posts

Next >>

How a truck transportation and logistics company leverages acquisitions and technology